国家卫健委：我国在研新药数量占全球数量的比例超过20%，跃居全球新药研发第二位

Core Insights - The National Health Commission of China reports that the number of new drugs under research in China accounts for over 20% of the global total, positioning the country as the second-largest in new drug development globally [1] - Several domestic innovative drugs, including Sugliatin, Ensatuximab, and Gumeitini, have been approved for market release, filling gaps in their respective fields of domestic innovation [1] - The self-developed anti-tumor drug Zebutinib has received approval for market release in multiple countries [1]